Imiquimod

Overview

Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 ( TLR7 ) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > HSV

Product Information

• Catalog No.: HY-B0180
• CAS No.: 99011-02-6
• Molecular Formula: C14H16N4
• Molecular Weight: 240.30
• Purity: 99.97%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Availability: In-stock

Source

Original product source